

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Previously presented) A method for killing glioma cancer cells in a subject wherein said glioma cancer cells express malignin, said method comprising administering to said subject an effective amount of a first dosage of a composition comprising malignin wherein said administration of said dosage stimulates the immune system of said subject to produce and release antimalignin antibody that binds and kills said glioma cancer cells.
2. (Previously presented) The method of claim 1 wherein the composition is administered as an approximately 1 mg dosage form.
3. (Original) The method of claim 1 further comprising administering a second dose of the composition ten days after administration of the first dosage.
4. (Original) The method of claim 3 further comprising administering a third dose of the composition ten days after administration of the second dosage.
- 5-6. (Canceled)
7. (Withdrawn) A device for removing cancer cells from the body of a subject, said device comprising cells having immunological specificity for malignin, recognin L or recognin M, wherein said device binds, absorbs or engulfs cancer cells which come into contact therewith.
8. (Withdrawn) The device of claim 7 wherein said device comprises a filter through which the cancer cells are passed.

9. (Withdrawn) The device of claim 7 wherein the device comprises a surface over which the cancer cells are passed.
10. (Withdrawn) The device of claim 7 wherein the device comprises a resin over which the cancer cells are passed.
11. (Withdrawn) The device of claim 7 wherein the cells are selected from the group consisting of T cells, B cells and phagocytes.
12. (Withdrawn) A process for ascertaining the presence of cells transformed to the malignant state in a subject
 - (1) obtaining a fluid or tissue specimen from the subject;
 - (2) quantifying the amounts of antimalignin antibody and/or immune cells having specificity for malignin, recognin L and/or recognin M in the fluid or tissue specimen;
 - (3) correlating the amounts to the presence of cells transformed to the malignant state.
13. (Withdrawn) An antimalignin antibody having a cytotoxic agent attached thereto.